Digital Ally Collaborates with Redwood Scientific to Combat Vaping
Digital Ally, Inc. (NASDAQ: DGLY) has entered a significant partnership with Redwood Scientific Technologies, securing exclusive distribution rights for groundbreaking anti-vaping products. This collaboration aims to address the pressing nicotine addiction issue faced by many.
Innovative Products to Curb Nicotine Dependency
As part of this agreement, Digital Ally will spearhead the commercialization of two innovative products: TBX-Free and TBX Vape-Free. The TBX Vape-Free product is particularly noteworthy, utilizing advanced oral thin-film technology specifically designed to help individuals dependent on vape devices. This strategy marks a revolutionary step in tackling nicotine addiction.
Details of the Agreement
The Master Distribution Agreement grants Digital Ally the global rights to distribute Redwood's full suite of nicotine cessation products. This arrangement includes access to Redwood's technology, trademarks, and manufacturing processes, enabling Digital Ally to position itself effectively in the market. The overarching goal is to provide consumers with novel solutions for overcoming vaping addictions.
Understanding the Market Need
According to the Centers for Disease Control and Prevention, about 11.6% of U.S. adults are current smokers, while 4.5% report using e-cigarettes. The prevalence of these habits highlights the critical need for effective cessation products. Cigarette smoking remains the leading cause of preventable disease in the US, with a staggering number of deaths attributed to it yearly.
Looking Ahead: Potential Impact on Public Health
Digital Ally’s CEO, Stan Ross, expressed pride in steering efforts against this public health crisis. With the final-stage clinical trials of Redwood’s products underway, the team anticipates a transformative approach to nicotine addiction treatment once the products hit the market.
Preparation for Market Launch
While marketing and sales of these innovative products won't commence until the clinical trials are completed, Digital Ally is already strategizing for full-scale distribution. This proactive approach ensures that, upon receiving approval, the products will be accessible to those who need them swiftly.
About Digital Ally, Inc.
Digital Ally, Inc. (NASDAQ: DGLY) specializes in video solution technologies, healthcare revenue cycle management, and other related services. The company is committed to integrating innovative technologies and maintaining a growth-driven model through strategic partnerships and acquisitions.
Contact Information
For further inquiries, you can reach Stanton E. Ross, CEO, at (913) 814-7774.
Frequently Asked Questions
What is the purpose of the partnership between Digital Ally and Redwood Scientific?
The partnership aims to distribute innovative nicotine cessation products, specifically targeting individuals addicted to vaping.
What products will Digital Ally distribute under this agreement?
Digital Ally will distribute TBX-Free and TBX Vape-Free, both designed to help consumers overcome nicotine addiction.
When will these products be available for sale?
The products will be launched following the successful completion of ongoing clinical trials.
Why is this agreement significant for public health?
This agreement provides access to effective solutions that aim to reduce the high rates of nicotine addiction in the U.S.
How does Digital Ally enhance its growth strategy?
Digital Ally focuses on acquiring innovative organizations and forming partnerships to boost its technological and market reach.
